DNYUZ
No Result
View All Result
DNYUZ
No Result
View All Result
DNYUZ
Home News

Inside the race to put computers in the human brain

November 21, 2026
in News
Inside the race to put computers in the human brain

A robotic arm drills a circle into the patient’s skull, then places a quarter-size device onto the brain tissue. Dangling from it are 64 wires, each thinner than a human hair. Electrodes along the wires pick up electrical signals from neurons in the brain, and the implant transmits that data to a phone or tablet. The patient can text friends, post on social media, and even play video games—all without lifting a finger.

That’s the promise of the N1 implant made by Neuralink, the brain-computer interface (BCI) company owned by Elon Musk. Neuralink has made science fiction a reality for the approximately 26 people using the device today in the product’s testing phase. All have severe disabilities, but Musk founded the company in 2016 with the goal of far broader adoption. In 2017 he argued that humans will need to connect our brains to technology to keep up with artificial intelligence and avoid “being left behind and being effectively useless, or like a pet.” By 2025, Neuralink was valued at roughly $9.7 billion.

Although no brain implants are on the U.S. market yet, the first one that becomes available will be a watershed moment—for the tech sector, for society, arguably for humanity—setting off what those in the industry expect to be a decades-long process to merge our minds with machines. BCIs stand to become increasingly interwoven in our everyday lives, spawning new businesses and demanding new norms to govern their use.

At stake for the companies pioneering these devices is a potentially massive market, both for the devices and the vast troves of data they’ll gather. For the rest of us, the question is what, if anything, we gain by giving corporations access to the sanctity of our thoughts—to profit off and perhaps even shape.

“What you’re thinking and feeling is your last space of true privacy. It’s the most fundamental aspect of what it means to be human,” says Nita Farahany, a professor at Duke University who authored a book on defending the freedom of thought in an era of brain implants. “We are rapidly heading toward a world of brain transparency, in which scientists, doctors, governments, and companies may peer into our brains and minds at will. Companies [could] know what products we want before we do.”


Neuralink is one in a growing field of U.S. companies developing BCIs, each sprinting to win Food and Drug Administration (FDA) approval for public sale. Those include Paradromics, which is focused on restoring speech, and Precision Neuroscience, which is pursuing a brain interface for patients with paralysis.

“It is definitely a race,” says Chad Bouton, CEO of the BCI company Neuvotion, which makes a commercially available, AI-guided wearable that can help restore movement in stroke and spinal cord injury patients. “I think in the next three or four years we might see an FDA clearance.”

Neuralink, with $1.3 billion in funding, more than double the next-best-funded brain implant company, might seem a shoo-in to come out ahead, but a rival BCI company, called Synchron, is neck and neck in the FDA process. Synchron’s device—which is less invasive and doesn’t require a skull-breaking craniotomy—may well be first to market.

Thomas Oxley, founder and CEO of Synchron, revealed to Fortune that his company has implanted its Stentrode device in 15 people, adding five more since last year. In that same period, Neuralink has gone from seven patients to 26. “They’re going fast,” said Oxley, who is himself a neurosurgeon.

The race had been underway for years before AI became a household term with the debut of ChatGPT in 2022. But rapidly advancing AI stands to dramatically enhance the power of brain implants by allowing them to better decipher our thoughts and intentions.

One day, AI-enhanced BCIs could enable us to control humanoid robots or AI agents on our behalf, taking instructions directly from our thoughts, says Matt Angle, CEO of Paradromics. As the research goes “cognitively upstream from language,” he says, the implants could know our desires before we are even aware of them. If a human is hungry, for example, “then the BCI would already understand what we are hungry for, and it would deduce the next reasonable thing,” Angle said—perhaps ordering food on a delivery app. “It won’t be mainstream right away,” he explained, but “it’ll come sooner than a lot of people are expecting.”

For workers, brain implants could usher in a new wave of employee surveillance in the name of productivity. Connecting a BCI to a work computer could help us type and navigate our computers faster, while also recording biological signals that reveal whether we are focused on work, or letting our minds wander. Employers could even nudge us back to work if BCIs develop two-way communication, Farahany writes in her book. She suspects punitive brain surveillance is unlikely to be tolerated by the public—but even today we accept new forms of workplace tracking, from how many times a day we badge-in to the office to transcriptions of what we say in meetings and monitoring of which applications we open on our computer.

“What you’re thinking and feeling is your last space of true privacy.”

NITA FARAHANY, AUTHOR AND DUKE UNIVERSITY PROFESSOR

Some argue that the “cyborgization” of humanity has already begun, even if the devices and algorithms that we’re joined with are external to the body. In a 2017 blog post titled “The Merge,” OpenAI CEO Sam Altman wrote, “Our phones control us and tell us what to do and when; social media feeds determine how we feel; search engines decide what we think.” By 2025, an OpenAI analysis of 1.5 million ChatGPT conversations found that roughly three-quarters concerned practical guidance, information seeking, or writing—suggesting that people are increasingly turning to AI to help decide what to do and what to say.

Altman cofounded the BCI company Merge Labs in 2025, and in early 2026, OpenAI invested in it. The company’s goal is to create a more “seamless” relationship with AI—presumably ChatGPT, or one of the models behind it. A Merge Labs spokesperson wasn’t ready to reveal its product yet in our conversation, but expects to have more to share in “a couple months.”

The portal to this new world will open when the FDA approves the first brain implant. Getting there is a long road for aspirants: Companies in the running must go through various stages, beginning with animal testing. Once they clear that hurdle, companies can perform their first human implant and begin what’s called “early feasibility studies.”

Then comes the pivotal study. Companies that reach this stage can expand to more patients, while also focusing on manufacturing. That means having the “whole manufacturing line established and frozen, [and] that’s a huge investment,” Oxley said.

It also means experimentation is largely over—device design is locked, and the final trials will assess the benefits for a specific, target user. The pivotal study concludes with FDA approval to sell the products to patients with eligible, clearly defined medical conditions, with insurance likely helping to cover the cost.


In 20 years, the BCI capabilities of today will likely seem rudimentary. But the technology is already capable of incredible things—no less than modern magic.

Neuralink’s first patient, Noland Arbaugh, who became paralyzed after a diving accident, has used the implant he had installed in January 2024 to play video games such as Civilization and is now working on a book in partnership with a writer.

His implant has enabled him to travel the world for speaking engagements and facilitated being in a relationship. Even though “being paralyzed still sucks,” he posted a few months ago, he’s “constantly blown away” by the advances of his implant. When I interviewed Arbaugh in 2025, he told me, “It has absolutely changed my outlook on life and what I’m able to accomplish and what I think I can do in the future. So it has given me a lot of hope for myself.”

Synchron patients can also manipulate a computer, and the company was the first to integrate with Apple’s newly created standardized, Bluetooth-powered BCI connection in 2025. But Synchron’s device, the Stentrode, is less powerful than Neuralink’s. That’s a downside of its being significantly less invasive, perhaps making it more palatable to patients who aren’t interested in the skull-drilling that Neuralink’s N1 requires.

Neuralink’s Patient No. 1, Noland Arbaugh.
Stuart Isett for Fortune

The Stentrode takes just a two-hour surgery to insert into a blood vessel near the brain, via a catheter, like a heart stent (hence the name). The sensor transmits electrical brain signals via a thin wire that tunnels under the skin to a coin-size “receiver,” embedded in the chest near the collarbone.

Synchron patients activate their implants by thinking about a part of the body, such as “Move my foot,” which an algorithm interprets as code for “Press select”—a less direct command than Neuralink’s, though miraculous in its own right.

Synchron, valued at nearly $1 billion in its latest funding round, is also cooking up a more powerful device, a major product launch Oxley says is coming “soon,” with a more explicit eye toward mass-market adoption. It will access more parts of the brain, not just one spot, like the Stentrode or Neuralink N1, and won’t require a craniotomy, Oxley said.

“Everyone in the field agrees that the holy grail of BCI is whole-brain sensing,” he said, explaining that the device could help patients with aging-related cognitive decline or dementia, behaving like a “cognitive copilot … I think that could be huge.” He framed it as a natural extension of the way today’s technology already helps us remember birthdays, auto-completes sentences in emails, or, using LLMs, writes presentations or understands our emotions.

Meanwhile, Neuralink is experimenting with less invasive techniques. In June 2026, Neuralink announced it had performed its first procedure without breaking a protective layer of the brain called the dura. This is a “big step,” says Adam Marblestone, cofounder of Convergent Research, an incubator for technical startups focused on the public good, and a former scientist at Google DeepMind. “I think that’s a kind of technical tour de force, and it probably leads to a very powerful system.”


As much as Neuralink and Synchron are competing against each other and other U.S. companies, they face perhaps even stiffer competition from China, where the world’s first commercially available BCI was approved in March. The industry there is “very fast, very active, and very dynamic,” Oxley said. When I asked if China’s rapid trajectory makes him nervous, he replied simply, “Yes.”

BCIs could introduce the same type of supply-chain risks as other tech that the U.S. grapples with China over—semiconductors, AI models, electric vehicles—but in a more extreme manner. If U.S. consumers’ brain implants or portions of their hardware are manufactured in China, could it risk giving the U.S. adversary access to American citizens’ secrets and internal monologues?

Europe has a BCI community of about five companies, including Spain’s InBrain, which is targeting treatment for conditions such as Parkinson’s disease. Science Corporation, an American BCI company led by Neuralink cofounder Max Hodak, received approval in Europe for its vision-restoring device in July 2026, and the company implanted its first patient in October.

Conversations about global BCI standards are just starting to happen. In 2025, Unesco (the United Nations Educational, Scientific, and Cultural Organization) published a recommendation on the ethics of neurotechnology, which 194 countries have signed on to. The agreement argues that society has an “ethical imperative” to develop BCIs, “particularly for medical and assistive use,” but it asks governments to establish safeguards to ensure that the technology benefits people without compromising their autonomy, freedom of thought, or mental privacy. Farahany was the U.S. State Department delegate who participated in the Unesco effort. She’s also working on a neurotechnology “trust index”—a voluntary rating system to measure companies’ performance against a set of core ethical commitments.

“The concerns are profound and large,” Farahany says. “It’s the ultimate merger. Where does the AI end, and where does the human begin, and vice versa?”

The post Inside the race to put computers in the human brain appeared first on Fortune.

A Brilliantly Ambivalent Memoir May Change How You See Nature Forever
News

A Brilliantly Ambivalent Memoir May Change How You See Nature Forever

by New York Times
November 21, 2026

YOSEMITE FALLS: Reckoning With California History and the Gospel of John Muir, by Daniel Duane Awe is cheap; the best ...

Read more
News

The False Comfort of Online Shopping

November 21, 2026
News

Body pulled from L.A. River following powerful storm, investigation underway

November 21, 2026
News

This actress relishes criminals and connivers. Now, she tackles the FTX collapse.

November 21, 2026
News

Trapped GOP chair admits grim truth after massive midterm wipeout

November 21, 2026
NYC inspectors ‘overlooked’ large cracks on doomed Brooklyn building years before it collapsed

NYC inspectors ‘overlooked’ large cracks on doomed Brooklyn building years before it collapsed

November 21, 2026
How to keep your houseplants healthy over the winter

How to keep your houseplants healthy over the winter

November 21, 2026
Inside the race to put computers in the human brain

Inside the race to put computers in the human brain

November 21, 2026

DNYUZ © 2026

No Result
View All Result

DNYUZ © 2026